Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.53 |
| ▸ | HTR2B | P41595 | 2/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | HRH2 | P25021 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5425845 | 1.00 | HTR1A (0.53) | HTR1AHTR2BHTR7HRH1DRD3 | |
| SCHEMBL13590304 | 1.00 | HTR1A (0.53) | HTR1AHTR2BHTR7HRH1DRD3 | |
| SCHEMBL14026300 | 0.92 | CHRM2 (0.52) | CHRM2 | |
| SCHEMBL14025291 | 0.92 | CHRM2 (0.52) | CHRM2 | |
| SCHEMBL13590296 | 0.92 | CHRM2 (0.52) | CHRM2 | |
| SCHEMBL13590421 | 0.92 | CHRM2 (0.52) | CHRM2 | |
| SCHEMBL13590468 | 0.92 | CHRM2 (0.52) | CHRM2 | |
| SCHEMBL14025278 | 0.92 | CHRM2 (0.54) | CHRM2 | |
| SCHEMBL13592245 | 0.92 | CHRM2 (0.54) | CHRM2 | |
| SCHEMBL13590536 | 0.92 | ACHE (0.49) | HTR1AHTR2BHTR7HRH1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208515-B2 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070032524-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2007-02-08 | — | — | US | disclosed |
| US-7151115-B2 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| EP-1725525-A1 | DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| US-7071224-B2 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060122182-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-06-08 | — | — | US | disclosed |
| WO-2005087722-A1 | DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050203161-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122182-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM5 | HTR1A 297/4885HTR2B 289/4885HTR7 483/4885 |
| US-20070032524-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM5 | HTR1A 297/4885HTR2B 289/4885HTR7 483/4885 |
| US-20050203161-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | HTR1A 269/4885HTR2B 238/4885HTR7 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.